Muhammad Akbar Ramadhan Munandar, Hendra Priatna Munandar, & Liana Herlina. (2026). Cost-Effectiveness of Pembrolizumab as First-Line Treatment for PD-L1 Positive NSCLC: A Systematic Review. The International Journal of Medical Science and Health Research, 23(2), 64-130. https://doi.org/10.70070/h3zdy035